Axolotl Biologix and Leonhardt Ventures to Study Combination Bioelectric and Biologic Therapies

Axolotl Biologix has announced a strategic partnership with Leonhardt Ventures to explore therapeutic and commercial opportunities of combining Leonhardt’s bioelectric + micro pump + mixed stem cell-based composition for organ regeneration with Axolotl Biologix’s amniotic-derived fluid products.
 
A major hurdle for regenerating damaged organs is to have the nutrients in place for recruited and infused stem cells to survive, thrive, differentiate and form new healthy organ tissues. Amniotic-derived fluid contains a variety of growth factors and cytokines that are optimized in the most regenerative environment known—the womb. This environment supports and encourages repair and regeneration.  
 
“We are very excited to explore whether the combination of bioelectric stimulation and our amniotic-derived fluid products can improve upon results found with either therapy on its own,” said Phillip Larson, president of Axolotl Biologix. “We believe that there is strong potential that there are synergistic benefits to this combination that will improve patient outcomes.” 
 
Howard Leonhardt, executive chairman and CEO of Leonhardt Ventures, added, “We are thrilled to work with Axolotl Biologix to develop, study, and potentially commercialize new combination bioelectric and biologic candidates for patients suffering from degenerative diseases. Axolotl Biologix’s expertise and experience in manufacturing amniotic-derived products is hugely helpful to our organ specific startups in developing their product pipelines.”
 
Through this partnership Axolotl Biologix will have access to Leonhardt’s expertise and technologies related to organ regeneration. This includes more than 19 patented or patent-pending  bioelectric  signaling sequences, re-fillable micro infusion pumps and stem cell based mixed compositions. Under the partnership, the Leonhardt Venture’s team and the 24 organ-specific startups in its  Leonhardt’s Launchpads innovation accelerator(s) in California and Utah will have access to Axolotl Biologix’s full lineup of amniotic-derived fluid technologies including AxioBioFluid A, an ambient room temperature amniotic-derived regenerative fluid product. 
 
Both Leonhardt’s Launchpads and Axolotl Biologix are committed to proving out these candidate combination therapies through properly designed and well-controlled clinical trials with good science applied.  
 
Axolotl Biologix Inc. is a biotechnology leader in regenerative medicine through research, technology, and clinical application. Phoenix, Ariz.-based Axolotl Biologix is expanding the human body’s ability to regenerate by developing and manufacturing regenerative human cell and tissue medical technologies that are disrupting traditional, more invasive, painful and expensive treatment protocols.
 
Operated by Cal-X Stars Business Accelerator Inc., Leonhardt’s Launchpads is the innovation and startup accelerator arm of Leonhardt Ventures and inventor Howard J. Leonhardt. The five-year accelerator is incubating 27 regenerative medtech and three regenerative economy startups and licensable technology platforms (LTPs). The accelerator has affiliated offices and labs in Playa Vista and Salt Lake City, Utah. Life science incubator/accelerator operations began in 2008 at the University of Northern California Science & Technology Innovation Center (UNC STIC) in Santa Rosa, Calif., under Leonhardt Ventures (Leonhardt Vineyards LLC DBA, Leonhardt Ventures founded in 2005). In 2013 the organization was incorporated and moved its headquarters to Los Angeles, Calif., where its primary headquarters are now.  
 
Founded in November 2015 in Salt Lake City, just off the campus of the University of Utah, Leonhardt’s Launchpads Utah is an organ regeneration focused innovation and startup accelerator. The company has lab space at the USTAR BioInnovations Gateway Utah facility and employs six biomedical engineers and biologists at this time, a local CPA and patent attorney, and has recruited a half dozen local Utah-based advisors.
 
Founded in 1982 as a sole proprietorship (HJ Leonhardt & Co.), Leonhardt Ventures (Leonhardt Vineyards LLC DBA Leonhardt Ventures) is the patent holding vehicle and venture capital arm of inventor Howard J. Leonhardt (formed into Califiornia LLC in 2005). In the 1980’s Leonhardt patented and developed a cardiovascular balloon catheter, in the 1990’s the leading stent graft system for endovascular aortic aneurysm repair and one of the first percutaneous heart valves and biological pacemakers. Since 2000 the focus has been on organ regeneration technologies with a combination of bioelectric signaling and repeat delivery of mixed stem cell + growth factor based compositions. More recently Leonhardt has added a strong estate of IP related to bioelectric cancer tumor treatment, real time inflammation and blood pressure management as well as a “brain saving helmet” designed for cerebral stroke and TBI patients. Leonhardt has over 21 issued U.S. patents with over 100 issued patent claims and dozens more pending. Leonhardt inventions have been used to treat more than 400,000 patients to date. Leonhardt’s Launchpads startups filed over 75 new U.S. patent claims in 2017.